Comment on CMS-2026-1255-0001

Summary: Vertex Pharmaceuticals Incorporated supports the proposed rule to modernize prior authorization (PA) through interoperability and reduced administrative burden. However, the company urges CMS to include specific safeguards, such as transparency requirements, expedited pathways for urgent therapies, and protections against increased PA volume or repeat authorizations for stable patients.